Talking About Tumors with Ryann and Ryan - A medical oncology podcast

02_05 Management of Metastatic Hormone Positive Breast Cancer

December 05, 2022 Talking About Tumors Season 2 Episode 5
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
02_05 Management of Metastatic Hormone Positive Breast Cancer
Show Notes

1.       Endocrine Resistance: Definition and Mechanism

2.       Role of AI with and without CDK4/6 inhibitors

3.       Later line management of metastatic disease

4.       Informative Censoring and the BOLERO-2 trial


As always, citations, and sources include education from our respective training programs, the Devita textbook, and  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017

2.           André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/

3.           Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371

4.           Piccart M et al.  Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456

5.           Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653

6.           Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6

7.           Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217

8.           Im SA  et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/

9.           Hortobagyi GN  et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/

10.        Finn RS  et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/

11.        Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/

12.        Robertson JFR  et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3

13.        Mauri D et al.   J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357

14.        Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482

15.        Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596



Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 


Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology